Chukwudi, Kelechi Nnaemeka and Adediji, Godwin and Lynch, Meghan and Scully, Michael and Keenan, Eamon (2026) Advancing opioid agonist treatment in Ireland: opportunities for expanded use of prolonged-release buprenorphine following the 2026 HSE funding allocation. Irish Journal of Psychological Medicine, Early online, pp. 1-3. https://doi.org/10.1017/ipm.2026.10239.
External website: https://pubmed.ncbi.nlm.nih.gov/42929385/
Recent budgetary developments within Ireland have increased funding for buprenorphine, including long-acting formulations, within publicly funded addiction services (Department of Health 2025). This policy shift represents an important opportunity to optimise OAT delivery and broaden treatment choice.
B Substances > Opioids (opiates) > Opioid product > Methadone
HJ Treatment or recovery method > Substance disorder treatment method > Substance disorder drug therapy (pharmacological treatment)
HJ Treatment or recovery method > Substance disorder treatment method > Substance replacement method (substitution) > Opioid agonist treatment (methadone maintenance / buprenorphine)
J Health care, prevention, harm reduction and treatment > Treatment and maintenance > Treatment factors
MP-MR Policy, planning, economics, work and social services > Financial management > Funding
VA Geographic area > Europe > Ireland
Repository Staff Only: item control page